DRUG
Bright Minds Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · CA
$65.60
−3.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 40.1K | — | — | — | — |
| Gross Profit | (40.1K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 33.2M | 11.1M | 1.2M | 5.0M | 12.2M |
| SG&A Expense | 6.3M | 2.6M | 1.4M | 2.2M | 2.6M |
| General & Admin Expense | 3.7M | 2.1M | 1.4M | 2.1M | 2.0M |
| Selling & Marketing Expense | 353.7K | 429.7K | 41.6K | 119.4K | 551.9K |
| Other Expenses | 332.8K | 287.6K | 197.2K | 186.7K | 243.1K |
| Total Operating Expenses | 39.8M | 13.9M | 2.8M | 7.4M | 15.0M |
| Cost and Expenses | 39.9M | 13.9M | 2.8M | 7.4M | 15.0M |
| Operating Income (EBIT) | (39.9M) | (13.9M) | (2.8M) | (7.4M) | (15.0M) |
| Non-Operating | |||||
| Interest Income | 6.9M | 1.5M | 30.1K | — | — |
| Interest Expense | 9.8K | — | — | — | — |
| Net Interest Income | 6.9M | 1.5M | 30.1K | — | — |
| Other Non-Op Income/Expense | 15.1M | 1.7M | 20.8K | 14.2K | 10.2K |
| Non-Operating Income (excl Interest) | (5.9M) | (1.7M) | (20.8K) | (14.2K) | (10.2K) |
| EBT (Pre-Tax Income) | (24.7M) | (12.2M) | (2.8M) | (7.4M) | (15.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (24.7M) | (12.2M) | (2.8M) | (7.4M) | (15.0M) |
| Earnings from Cont. Ops | (24.7M) | (12.2M) | (2.8M) | (7.4M) | (15.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.7M) | (12.2M) | (2.8M) | (7.4M) | (15.0M) |
| Per Share | |||||
| Basic EPS | ($2.76) | ($1.78) | ($0.65) | ($1.98) | ($6.15) |
| Diluted EPS | ($2.76) | ($1.78) | ($0.65) | ($1.98) | ($6.15) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 9.8M | 6.9M | 4.3M | 3.7M | 2.5M |
| Diluted Shares Outstanding | 9.8M | 6.9M | 4.3M | 3.7M | 2.5M |
| Profitability Metrics | |||||
| EBITDA | (33.9M) | (12.2M) | (2.7M) | (7.3M) | (15.0M) |
| D&A | 76.9K | 76.9K | 73.4K | 72.5K | 6.0K |
| EBIT | (34.0M) | (12.2M) | (2.8M) | (7.4M) | (15.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026